3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl]propanenitrile

• ChemBase ID: 1372
• Molecular Formular: C18H13ClFN3O2
• Molecular Mass: 357.7661232
• Monoisotopic Mass: 357.06803257
• SMILES: Clc1cc2c(N(CCC#N)C(=O)C(O)N=C2c2c(F)cccc2)cc1
• Canonical SMILES: N#CCCN1C(=O)C(O)N=C(c2c1ccc(c2)Cl)c1ccccc1F
• InChI: InChI=1S/C18H13ClFN3O2/c19-11-6-7-15-13(10-11)16(12-4-1-2-5-14(12)20)22-17(24)18(25)23(15)9-3-8-21/h1-2,4-7,10,17,24H,3,9H2
• InChIKey: XAXMYHMKTCNRRZ-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl]propanenitrile
• IUPAC Traditional name: cinolazepam
• Brand Name: Gerodorm
• Synonyms: Cinolazepamum [inn-latin]; Cinolazepam

Database IDs

• CAS Number: 75696-02-5
• PubChem SID: 160964832; 46508803
• PubChem CID: 3033621

CALCULATED PROPERTIES

JChem

• Acid pKa: 10.675213
• H Acceptors: 4
• H Donor: 1
• LogD (pH = 5.5): 2.7029908
• LogD (pH = 7.4): 2.7027636
• Log P: 2.7029936
• Molar Refractivity: 90.99 cm^3
• Polarizability: 34.213543 Å^3
• Polar Surface Area: 76.69 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 2.42
• LOG S: -4.48
• Solubility (Water): 1.20e-02 g/l

DETAILS

DrugBank - DB01594

• Drug Groups: approved
• Description: Cinolazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Cinolazepam is not approved for sale in the United States or Canada.
• Indication: For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
• Pharmacology: Cinolazepam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Cinolazepam is not approved for sale in the United States or Canada.
• Toxicity: The onset of impairment of consciousness is relatively rapid in benzodiazepine poisoning. Onset is more rapid following larger doses and with agents of shorter duration of action. The most common and initial symptom is somnolence. This may progress to coma Grade I or Grade II following very large ingestions.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic.
• Absorption: Bioavailability following oral administration is 90-100%.
• Half Life: 9 hours
• External Links: Wikipedia